5 results on '"Cao, Jiawei"'
Search Results
2. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
- Author
-
Cai S, Cao J, Yu T, Xia M, and Peng J
- Subjects
- Adult, Antiviral Agents adverse effects, Drug Resistance, Viral, Female, Follow-Up Studies, Guanine adverse effects, Guanine therapeutic use, Hepatitis B e Antigens, Hepatitis B virus genetics, Hepatitis B, Chronic virology, Humans, Logistic Models, Male, Multivariate Analysis, ROC Curve, Retreatment, Telbivudine, Thymidine adverse effects, Thymidine therapeutic use, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Guanine analogs & derivatives, Hepatitis B, Chronic drug therapy, Interferons therapeutic use, Thymidine analogs & derivatives
- Abstract
Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B virus (HBV) infection. Treatment parameters included virological response, hepatitis B e antigen (HBeAg) seroconversion, and alanine aminotransferase (ALT) normalization.Of 180 patients studied, 56 received de novo telbivudine monotherapy (LDT group); 45 received entecavir monotherapy (ETV group); 40 received LDT following interferon (interferon-telbivudine [IFN-LDT] group); and 39 received ETV following interferon (interferon-entecavir [IFN-ETV] group). At week 52, virological response occurred in significantly more patients in the IFN-ETV group than the ETV group (87.2% vs 57.8%, P = .003). At week 104, HBeAg seroconversion occurred in significantly more patients in the IFN-ETV group than the ETV group (44.4% vs 22.2%, P = .03). At week 52, virological response was achieved by significantly more patients in the IFN-LDT group than the LDT group (85.0% vs 64.3%, P = .02).This study showed that switch to rescue therapy with ETV or LDT therapy after failure of interferon therapy resulted in more rapid virologic response than with de novo treatment with either ETV or LDT; rescue therapy with ETV resulted in a greater HBeAg seroconversion rate.
- Published
- 2017
- Full Text
- View/download PDF
3. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
- Author
-
Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen HLA, and Peng J
- Subjects
- Adult, Alanine Transaminase blood, Asian People, Endpoint Determination, Female, Follow-Up Studies, Hepatitis B Surface Antigens blood, Hepatitis B Surface Antigens immunology, Hepatitis B e Antigens blood, Hepatitis B e Antigens immunology, Hepatitis B virus drug effects, Humans, Limit of Detection, Liver pathology, Male, Middle Aged, Prospective Studies, Recurrence, Risk Factors, Treatment Outcome, Antiviral Agents pharmacology, DNA, Viral isolation & purification, Hepatitis B virus isolation & purification, Hepatitis B, Chronic drug therapy, Nucleosides pharmacology, Nucleotides pharmacology
- Abstract
Background: The optimal management remains unknown after nucleos(t)ide analogue (NA) discontinuation in patients with chronic hepatitis B (CHB). This prospective study investigated the role of off-treatment viral kinetics in predicting relapse after discontinuation of NA therapy., Methods: A total of 82 noncirrhotic Asian patients with CHB who discontinued NA therapy according to international guidelines were prospectively followed. Patients with a hepatitis B virus (HBV) DNA level of >2000 IU/mL and an alanine aminotransferase (ALT) level of >2 times the upper limit of normal (clinical relapse) were retreated., Results: Sixty patients were HBV envelope antigen (HBeAg) positive at the start of treatment, and 22 were HBeAg negative. Clinical relapse developed in 28 patients (2-year rates, 31% among HBeAg-positive patients and 53% among HBeAg-negative patients). Age of ≤35 years (hazard ratio [HR], 0.37; P = .026) and end-of-treatment HBsAg level of ≤200 IU/mL (HR, 0.39; P = .078) were independently associated with lower relapse rates. A high risk of biochemical relapse (defined as an ALT level of >2 times the upper limit of normal) was observed if the HBV DNA level was >200000 IU/mL when the level was initially elevated, compared with HBV DNA levels of >2000 to ≤200000 IU/mL (HR, 8.42; P < .001). The risk of biochemical relapse was also high in patients with persistent elevation in the HBV DNA level (confirmed to be >2000 IU/mL within 3 months), compared with the group with transient elevation (HR, 6.87; P < .001)., Conclusions: After NA discontinuation, a lower relapse rate was observed in younger patients and in those with low end-of-treatment HBsAg levels. The level and persistence of off-treatment elevated HBV DNA levels were useful in the prediction of a subsequent biochemical relapse and may thus be used to guide off-treatment management., (© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
4. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.
- Author
-
Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, and Sun J
- Subjects
- Adult, Age Factors, Cohort Studies, Female, Hepatitis B Surface Antigens blood, Hepatitis B, Chronic blood, Hepatitis B, Chronic etiology, Humans, Male, Recurrence, Treatment Outcome, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Nucleosides therapeutic use, Nucleotides therapeutic use
- Abstract
Background/aims: The aim of this study was to identify the predictors for relapse after discontinuation of oral nucleos(t)ide analog treatment for chronic hepatitis B (CHB)., Patients and Methods: We evaluated patients who were receiving long-term, regular antiviral therapy with nucleos(t)ide analogs, and subsequently achieved the discontinuation criteria from the Asia-Pacific guideline. After they voluntarily discontinued the drug therapy, data were prospectively collected to observe the potential virologic relapse, and the parameters that predicted recurrence were analyzed., Results: Sixty-five patients met the inclusion criteria, and were included in this study. Twenty-eight patients relapsed, and the accumulative recurrence rates at the 3-month, 6-month, and 1-year follow-ups were 13.85%, 32.31%, and 49.23%, respectively. There was no difference in the accumulative recurrence rate 12 months after discontinuation among patients who were positive or negative for the hepatitis B e antigen (HBeAg) before they received the medication. Logistic regression analysis revealed that the time to complete response, age at discontinuation, and HBsAg levels at discontinuation affected the rate of relapse., Conclusions: Among patients who received orally administrated nucleos(t)ide analogs, serum levels of HBsAg, age at discontinuation, and the time to complete response might be used as a guide to discontinue treatment. Among younger patients, those with low serum HBsAg levels, and those with an earlier complete response, the risk of relapse is lower and discontinuation is much safer.
- Published
- 2015
- Full Text
- View/download PDF
5. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
- Author
-
Jiawei Cao, Heng Chi, Tao Yu, Zhandong Li, Hansen, Bettina E., Xiaoyong Zhang, Chunxiu Zhong, Jian Sun, Jinlin Hou, Janssen, Harry L. A., Jie Peng, Cao, Jiawei, Chi, Heng, Yu, Tao, Li, Zhandong, Zhang, Xiaoyong, Zhong, Chunxiu, Sun, Jian, Hou, Jinlin, and Peng, Jie
- Subjects
HEPATITIS B treatment ,DISEASE relapse ,CHRONIC hepatitis B ,NUCLEOTIDES ,ALANINE aminotransferase ,THERAPEUTICS ,ANTIVIRAL agents ,ASIANS ,BIOLOGICAL assay ,DNA ,HEPATITIS viruses ,LIVER ,LONGITUDINAL method ,NUCLEOSIDES ,VIRAL antigens ,TREATMENT effectiveness ,PHARMACODYNAMICS - Abstract
Background: The optimal management remains unknown after nucleos(t)ide analogue (NA) discontinuation in patients with chronic hepatitis B (CHB). This prospective study investigated the role of off-treatment viral kinetics in predicting relapse after discontinuation of NA therapy.Methods: A total of 82 noncirrhotic Asian patients with CHB who discontinued NA therapy according to international guidelines were prospectively followed. Patients with a hepatitis B virus (HBV) DNA level of >2000 IU/mL and an alanine aminotransferase (ALT) level of >2 times the upper limit of normal (clinical relapse) were retreated.Results: Sixty patients were HBV envelope antigen (HBeAg) positive at the start of treatment, and 22 were HBeAg negative. Clinical relapse developed in 28 patients (2-year rates, 31% among HBeAg-positive patients and 53% among HBeAg-negative patients). Age of ≤35 years (hazard ratio [HR], 0.37; P = .026) and end-of-treatment HBsAg level of ≤200 IU/mL (HR, 0.39; P = .078) were independently associated with lower relapse rates. A high risk of biochemical relapse (defined as an ALT level of >2 times the upper limit of normal) was observed if the HBV DNA level was >200000 IU/mL when the level was initially elevated, compared with HBV DNA levels of >2000 to ≤200000 IU/mL (HR, 8.42; P < .001). The risk of biochemical relapse was also high in patients with persistent elevation in the HBV DNA level (confirmed to be >2000 IU/mL within 3 months), compared with the group with transient elevation (HR, 6.87; P < .001).Conclusions: After NA discontinuation, a lower relapse rate was observed in younger patients and in those with low end-of-treatment HBsAg levels. The level and persistence of off-treatment elevated HBV DNA levels were useful in the prediction of a subsequent biochemical relapse and may thus be used to guide off-treatment management. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.